Login / Signup

The therapeutic benefits of combined sorafenib and transarterial chemoembolization for advanced hepatocellular carcinoma.

Teng-Yu LeeTeng Yu LeeYen Chun PengSheng Shun YangHong Zen YehChi Sen Chang
Published in: Journal of digestive diseases (2020)
Combined sorafenib and TACE therapy has significant better outcomes than sorafenib alone in patients with stage C HCC, particularly those with MVI.
Keyphrases
  • radiofrequency ablation
  • type diabetes
  • metabolic syndrome
  • liver metastases
  • cell therapy
  • weight loss